Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...

The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...

Company appoints Anil K. Sood, MD, as inaugural member Company continues to advance lead program, KAD101 for the treatment of ...

The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.

Bianca Muñiz, a three-time cancer survivor first diagnosed at age 11, shared her powerful story on International Childhood ...

Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovarian cancer and other solid tumours. Suitable for ...

Reseachers from WEHI (Melbourne, Australia) have found a new way to predict a subset of patients who are likely to become ...

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

Ovarian cancer is the sixth most common cancer in women in the UK but the symptoms can be quite subtle, often leaving to a ...